Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 54th Ann...
September 24 2018 - 7:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that
clinical data for sotagliflozin will be presented at the upcoming
European Association for the Study of Diabetes (EASD) 54th annual
meeting (October 1-5, Berlin, Germany). Sotagliflozin is an oral
treatment under investigation for use as an adjunct to insulin
therapy to improve glycemic control in adults with type 1 diabetes.
The accepted abstracts, including one oral presentation, reflect
Lexicon’s and its collaborator, Sanofi’s efforts to address the
unmet need for new options for the management of type 1 diabetes.
Oral Presentation (all times
local)
- Wednesday, October 3, 2:30 pm-4:00 pm
- “The inTandem 2 study: 52-week efficacy and safety of
sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy
to insulin in adults with type 1 diabetes” (#112)
Posters
- Tuesday, October 2, 1:15 pm-2:15 pm
- “The inTandem1 study: 52-week efficacy and safety of
sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy
to insulin in adults with type 1 diabetes” (#609)
- “inTandem1 and inTandem2: increased time in range with
sotagliflozin as adjunct therapy to insulin in adults with type 1
diabetes by 24-week continuous glucose monitoring"
(#610)
- “Sotagliflozin in combination with optimised insulin therapy
reduced HbA1c levels with a decreased daily insulin requirement
after 52 weeks in adults with type 1 diabetes” (#611)
- “Sotagliflozin further improves percentage of patients
achieving HbA1c goal without weight gain in adults with type 1
diabetes after insulin therapy optimization” (#614)
- “Patients with type 1 diabetes value increased glucose
stability and associate it with improved well-being: exit
interviews from sotagliflozin Phase 3 study” (#615)
- Wednesday, October 3, 12:00 pm-1:00 pm
- “Effect of sotagliflozin on renal threshold for glucose
reabsorption and on gastrointestinal glucose absorption in subjects
with type 2 diabetes: a model based quantification” (#624)
About Sotagliflozin
Discovered using Lexicon’s unique approach to
gene science, sotagliflozin is an investigational oral dual
inhibitor of two proteins responsible for glucose regulation known
as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
SGLT1 is responsible for glucose absorption in the gastrointestinal
tract, and SGLT2 is responsible for glucose reabsorption by the
kidney.
Lexicon entered into a collaboration and license
agreement with Sanofi in November 2015 under which Lexicon granted
Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing
right and license to develop, manufacture and commercialize
sotagliflozin. Lexicon is responsible for all clinical development
activities relating to type 1 diabetes and has exercised an
exclusive option to co-promote and have a significant role, in
collaboration with Sanofi, in the commercialization of
sotagliflozin for the treatment of type 1 diabetes in the U.S.
Sanofi is responsible for all clinical development and
commercialization of sotagliflozin for the treatment of type 2
diabetes worldwide (excluding Japan) and is solely responsible for
the commercialization of sotagliflozin for the treatment of type 1
diabetes outside the U.S. (excluding Japan). A New Drug Application
and a Marketing Authorization Application for sotagliflozin are
currently under review at the U.S. Food and Drug Administration and
the European Medicines Agency, respectively, and the product has
not yet been approved for use in the U.S. or in Europe.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company that is applying a unique approach to gene science based on
Nobel Prize-winning technology to discover and develop precise
medicines for patients with serious, chronic conditions. Through
its Genome5000™ program, Lexicon scientists have studied the role
and function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO® (telotristat ethyl), Lexicon has a
pipeline of promising drug candidates in clinical and pre-clinical
development in diabetes and metabolism and neuropathic pain. For
additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s and
Sanofi’s clinical development of and regulatory filings for
sotagliflozin and the potential therapeutic and commercial
potential of sotagliflozin. In addition, this press release also
contains forward-looking statements relating to Lexicon’s growth
and future operating results, discovery, development and
commercialization of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including the risk that the FDA and other regulatory authorities
may not grant regulatory approval of sotagliflozin in accordance
with Lexicon’s currently anticipated timelines or at all, and the
risk that such regulatory approvals, if granted, may have
significant limitations on the approved use of sotagliflozin. As a
result, sotagliflozin may never be successfully commercialized.
Other risks include Lexicon’s ability to meet its capital
requirements, successfully commercialize XERMELO (telotristat
ethyl), successfully conduct preclinical and clinical development
and obtain necessary regulatory approvals of LX2761, LX9211 and its
other potential drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon’s actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under “Risk Factors” in Lexicon’s annual report on Form
10-K for the year ended December 31, 2017, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From May 2023 to May 2024